Novartis India Limited

September 08, 2026

To,
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500672

Sub.: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Schedule III Part A Para B sub-para 5 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), read with the Company's Policy for Determination of Materiality of Events or Information, we hereby inform that Novartis India Limited (the "**Company**") has entered into an Exclusive Promotion and Distribution Agreement dated 8th September 2026 with Novartis Healthcare Private Limited ("**NHPL**").

Under the terms of the said Agreement, the Company has been granted the rights to exclusively promote and distribute NHPL's retina portfolio comprising the products Accentrix® (ranibizumab) and Pagenax® (brolucizumab) for the territory of India. The Agreement is expected to support the Company's entry into the ophthalmology therapy area and expand its commercial portfolio.

The brief details of the same are attached as **Annexure I**.

The above is for your information and the same is also available on the website of the Company i.e. www.nilpharma.co.in

Thank you.
For Novartis India Limited

CHANDNI BHUPENDRA MARU
Digitally signed by CHANDNI BHUPENDRA MARU
Date: 2026.09.08 09:17:06 +05'30'

Chandni Maru
Company Secretary and Compliance Officer
A60291
Encl.: as above

Disclosure in terms of SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Annexure I

Sr. No	Particulars	Details
a)	Name of Parties to the Agreement	Novartis India Limited (NIL) and Novartis Healthcare Private Limited (NHPL)
b)	Purpose of entering into the Agreement	Exclusive Distribution and Promotion Agreement to distribute and promote NHPL's retina portfolio comprising the products Accentrix® (ranibizumab) and Pagenax® (brolucizumab) in India.
c)	Size of Agreement	The upfront consideration payable by the Company to NHPL shall be INR 10 Crores (Indian Rupees Ten Crores).
d)	Shareholding, if any, in the entity with whom the Agreement is executed	Nil
e)	Significant terms of the Agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Not Applicable
f)	Whether the said Parties are related to Promoter/Promoter Group/Group Companies in any manner. If yes, nature of relationship.	No
g)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	No
h)	In case of issuance of shares to the Parties, details of issue price, class of shares issued	Not Applicable
i)	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of	Not Applicable

	the loan agreement/sanction letter, details of the security provided to the lenders/ by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	
J)	Any other disclosures related to such agreements, viz., details of nominee on the Board of Directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not Applicable
k)	In case of termination or amendment of Agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of Parties to the Agreement; ii. nature of the Agreement; iii. date of execution of the Agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable